

# SCIENTIFIC REPORTS



OPEN

## Novel Bioinformatics–Based Approach for Proteomic Biomarkers Prediction of Calpain-2 & Caspase-3 Protease Fragmentation: Application to $\beta$ II-Spectrin Protein

Atlal El-Assaad<sup>1</sup>, Zaher Dawy<sup>1</sup>, Georges Nemer<sup>2</sup> & Firas Kobeissy<sup>2</sup>

Received: 18 May 2016  
Accepted: 15 December 2016  
Published: 23 January 2017

The crucial biological role of proteases has been visible with the development of degradomics discipline involved in the determination of the proteases/substrates resulting in breakdown-products (BDPs) that can be utilized as putative biomarkers associated with different biological-clinical significance. In the field of cancer biology, matrix metalloproteinases (MMPs) have shown to result in MMPs-generated protein BDPs that are indicative of malignant growth in cancer, while in the field of neural injury, calpain-2 and caspase-3 proteases generate BDPs fragments that are indicative of different neural cell death mechanisms in different injury scenarios. Advanced proteomic techniques have shown a remarkable progress in identifying these BDPs experimentally. In this work, we present a bioinformatics-based prediction method that identifies protease-associated BDPs with high precision and efficiency. The method utilizes state-of-the-art sequence matching and alignment algorithms. It starts by locating consensus sequence occurrences and their variants in any set of protein substrates, generating all fragments resulting from cleavage. The complexity exists in space  $O(mn)$  as well as in  $O(Nmn)$  time, where  $N$ ,  $m$ , and  $n$  are the number of protein sequences, length of the consensus sequence, and length per protein sequence, respectively. Finally, the proposed methodology is validated against  $\beta$ II-spectrin protein, a brain injury validated biomarker.

Degradomics discipline has been recently introduced to depict the application of an omics approach (genomics and proteomics etc.) to identify different proteases and their subsequent proteolytic substrates/degradome in a defined pathophysiological condition<sup>1</sup>. Recently, the use of bioinformatics tools as means for data mining has spanned different fields in cancer, neuroscience and biochemistry research<sup>2,3</sup>. Degradomics as a discipline has benefitted from data mining strategies as tools to predict degradome specific substrates *in silico*<sup>4-7</sup>. However, the application of bioinformatic tools on degradomics analysis requires different types of sequencing matching algorithms making it one of the challenging fields despite its potential beneficial outcomes mainly in clinical and diagnostic research. Knuth *et al.* developed an algorithm that only finds exact matches of a subsequence of size  $m$  in a sequence of size  $n$  in  $O(m + n)$ <sup>8</sup>. It is worth to know that other algorithms have identified sequence variants with comparable complexity, but not with the same fidelity. Lipman *et al.* devised a heuristic algorithm called FAST Protein (FASTP)<sup>9</sup>; it is based on alignment approach and is both rapid and sensitive in finding similarities between any amino acid subsequence and matching sequences in a database. Yet, it does not cover all regions, as it starts with an anchoring scheme that identifies identical regions using a replaceability matrix<sup>9</sup>. Similarly, Altschul *et al.* developed another heuristic algorithm BLAST, along with its variations; this algorithm supposedly supersedes FASTP in performance while retaining comparable sensitivity<sup>10</sup>. Nonetheless, it also uses seeds for basic anchoring as it identifies similar sequences to the query sequence by seeking segment pairs comprising a word pair of a given score.

<sup>1</sup>Department of Electrical and Computer Engineering, American University of Beirut, Riad El Solh, Beirut, Lebanon.

<sup>2</sup>Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Riad El Solh, Beirut, Lebanon. Correspondence and requests for materials should be addressed to Z.D. (email: zd03@aub.edu.lb) or F.K. (email: firasko@gmail.com)

In contrast, Ning *et al.* devised a sequence search and alignment algorithm based on the Sequence Search and Alignment by Hashing Algorithm (SSAHA); this method performs three to four times faster than FASTP or BLAST, as it handles searches in databases of gigabyte range<sup>11</sup>. However, it is associated with overhead as it pre-processes the sequences in the database by breaking them into consecutive k-tuples, and then uses a hash-table to store the position of each k-tuple occurrence. Ma *et al.* devised another search algorithm that works faster than BLAST, with both a modest memory usage and higher sensitivity, covering a wider seeding model<sup>12</sup>. Nevertheless, it is also based on heuristics, compromising accuracy to a certain extent. Kurtz *et al.* developed a suffix tree-based method for similarity sequence search, implemented with linked lists<sup>13</sup>. This method performs well, but is limited to exact searches and suffers from overhead due to large space requirements, with continual and necessary updates requirements to the linked lists. Lecroq developed an algorithm based on the Q-gram hashing; it is considered the fastest so far, especially on a small size alphabet, because it searches the sequence database using an efficient indexing technique<sup>14</sup>. Nonetheless, it is also limited to searching for exact matches. Needleman *et al.* created the first method for biological sequence comparison based on dynamic programming<sup>15</sup>. Even though this method is considered to be optimal, it is based on global alignment, which renders it more specific to sequences of comparable sizes.

Applications of degradomics studies have been witnessed in several diseases, such as brain injury and cancer<sup>6,7,16,17</sup>. In brain injury field, both calpain-2 and caspase-3 proteases generate signature protein markers that would theoretically be indicative of different types of neural cell injury mechanisms<sup>16–18</sup>. These signature markers are fragment proteins or BDPs, resulting from proteases-associated cleavages. Since they are differentiated by their sequence and molecular weight (Mwt) specificity, they are considered unique to each protease with a definitive signature Mwt characterized by a well-defined amino acid sequence. Degradomics-peptidomics profiling of blood plasma, for instance, showed high sensitivity to changes not evidenced by standard proteomics techniques, providing unique signatures of diagnostic utility<sup>19</sup>.

In cancer research, Itoh *et al.* presented a review of the intense role of MMPs in cancer disease. Metalloproteases, MMP-2 and MMP-9, generate protein substrate fragments that are indicative of malignant growth<sup>20</sup>. Similarly, Fuhrman-Luck *et al.* used degradomics studies to identify kallikrein-related peptidase (KLK) substrates as biomarkers for cancer disease<sup>21</sup>. In Lopez-Otin *et al.* work, the local degradation of extra cellular matrix (ECM) forming the physical barrier for cell migration components is observed due to the activation of matrix MMPs<sup>22</sup>. MMPs, similar to other proteases (caspases, calpains and cathepsins) can truncate proteins at specific amino acid sequences<sup>20,22</sup>.

On the other hand, degradomics studies have been noticeable in the genetic aspects of congenital heart disease (CHD) since they represent major causes of birth defects in newborns. A crucial gene in this context is the *TLL1* which encodes a metalloprotease. Upon activation, this metalloprotease truncates extracellular substrate proteins in the septum and the resulting BDPs represent putative markers of the disease<sup>23</sup>. Moreover, degradomics studies have contributed significantly to the field of neuroscience particularly in neural injury conditions. Glantz *et al.* discerned the molecular basis of protease-catalyzed proteolysis of  $\alpha$ II-spectrin and  $\beta$ II-spectrin in the different injury scenarios, indicative of different neural injury techniques (both apoptotic and necrotic)<sup>24</sup>.


The main potential of this work lies in its ability to predict fragments sequences computationally prior to wet experiments. This work extends on previous research in identifying brain injury specific BDPs, utilizing data of different potential substrate proteins, extracted from public databases<sup>25</sup>. The goal is to computationally search through the set of selected proteins for potential breakdown sites (consensus exact matches as well as variants), subject to fragmentation, and subsequently generate all possible cleaved fragments (BDPs). The work presents a dynamic programming solution based on modifications to the Smith-Waterman (SW) algorithm. Accordingly, the solution is based on local alignment and runs in time and space complexity  $O(mn)$  per protein sequence ( $m$  and  $n$  represent the sizes of the consensus sequence as well as the protein sequence, respectively). The method is applied to calpain-2 and caspase-3 proteases which are associated with the execution phase of both the apoptotic and necrotic cell death, and where the distinction between the two dominated types of cell death is crucial to better reveal the injury mechanisms.

This paper is organized as follows: We first describe the results of applying the computational method to the cleavage of  $\beta$ II-spectrin substrates, particularly in brain injury. It then describes the implicated proteases calpain-2 and caspase-3 as well as the distinction between the associated neural cell deaths (necrosis/apoptosis). After elaborating on the cleavage modes of calpain-2 and caspase-3, the results section presents the generated data for both the  $\beta$ II-spectrin protein and the mouse genome used in testing the algorithm and the corresponding output results. Afterwards, discussion of output is presented in the discussion section. Finally, the methods section defines the main problem and then describes the method and the algorithm involved in more details.

## Results

**Calpain-2 and Caspase-3 Proteases.** Both calpain-2 and caspase-3 are activated in different modes of neural cell death and; thus, it is essential to characterize their spatio-temporal activation as it is indicative of the injury mechanisms. Calpain-2 protease is activated in necrosis and apoptosis; it generates calpain-specific cleaved fragments. On the other hand, caspase-3 protease is only activated in neural apoptosis and generates caspase-specific cleaved fragments. Both of these proteases cleave their associated protein substrates at a cleavage site predefined within each consensus occurrence resulting in unique BDPs. Since the BDPs are differentiated by their protease-generated molecular weight (see Fig. 1), they are specific to each protease and represent molecular signatures<sup>16,18,26</sup>.

In order to characterize the possible cleavage fragments of an already characterized protein, we assessed the brain injury biomarker  $\beta$ II-spectrin with its BDPs post calpain-2 and caspase-3 activation. We apply our proposed *Cleaved Fragments Prediction Algorithm for Calpain and Caspase (CFPA-CalpCasp)*, that is specifically designed to assess calpain-2 and caspase-3 cleavage substrate sequences<sup>25</sup>. The algorithm is based on dynamic programming



**Figure 1. Schematic of necrosis and apoptosis cell death pathways.** Figure shows necrosis type of neuronal cell death on the right, with calpain-2 specific fragments SBDP110 and SBDP85. On the left, the figure shows apoptosis neuronal cell death type, with caspase-3 specific fragments SBDP108 and SBDP80. The fragments are labeled with their approximate sizes. On the bottom, the figure shows the breakdown products by order of generation. First, calpain-2 cleaves  $\beta$ II-spectrin and generates SBDP110. Afterwards, and if both of caspase-3 and calpain-2 are activated, SBDP110 is cleaved by both proteases, generating SBDP108 and SBDP85. Lastly, caspase-3 cleaves SBDP85 and produces SBDP80 (apoptosis-specific)<sup>16,32</sup>.

	Calpain	Caspase
Protease Class	Cysteine Protease	Cysteine Protease
Preferred Cleavage Site (*)	Asp $\times$ xAsp $\times$ x	(Leu, Val, Ile) $\times$ x $\times$
Common Substrates	$\alpha$ II-spectrin 280 kDa	$\alpha$ II-spectrin 280 kDa
	$\beta$ II-spectrin 260 kDa	$\beta$ II-spectrin 260 kDa
Fragments Produced by	SBDP110 kDa	SBDP108 kDa
$\beta$ II-spectrin	SBDP85 kDa	SBDP80 kDa
Cell Death Involvement	Most forms of necrosis	Most forms of apoptosis
	Some forms of apoptosis	

**Table 1. Calpain-2 and Caspase-3 Cleavage Properties.** The table shows the different properties specific to calpain and caspase. Most importantly, it shows the consensus patterns at which each of the proteases cleaves. For caspase protease, the consensus pattern is DXXD and the cleavage site is right after this pattern (D is Aspartic Acid and X is any amino acid). Calpain, on the other hand, cleaves after the consensus patterns LX, VX, or IX, where L is Leucine, V is Valine, and I is Isoleucine.

principles and is efficient in terms of both time and ‘Space Complexity’ (Run time) complexity. This algorithm is capable of performing local sequence alignment achieved via a scoring table; in addition, it is able to find consensus occurrences and variants of the consensus sequence after accounting for insert and delete operations<sup>27</sup>.

The algorithm CFPA-CalpCasp proved its effectiveness after validating its results against experimental studies from previous works in the literature. This allows the utilization of the proposed computational methodology to guide and complement further experimental studies. Both of calpain-2 and caspase-3 proteases can lead to different cleaved fragments depending on whether the activation is combined or separate. The following three subsections illustrate the three different cases of when caspase-3 is activated separately, then when calpain-2 is activated separately, and finally when both of caspase-3 and calpain-2 are activated together (see summary in Table 1).

**Caspase-3 Cleavage Mode (Apoptosis).** Caspase-3, similar to calpain-2, is a cytosolic cysteine protease. However, caspase-3 differs from calpain-2 in the requirement for  $\text{Ca}^{2+}$ . Furthermore, what distinguishes caspase-3 from other proteases is that it has a crucial role in apoptosis in many different cell types<sup>27</sup>. When caspase-3 is activated, it functions as a downstream mediator in apoptosis and exclusively generates  $\beta$ II-spectrin BDP specific fragment “SBDP108”. Caspase-3 cleaves the substrate after finding both of Asp in the first position (P1 position) and Asp in the fourth (P4 position), whereas any amino acids can occupy the second position (P2 position) and the third position (P3 position), as indicated in Table 1<sup>18</sup>.

**Calpain-2 Cleavage Mode (Necrosis and Apoptosis).** The association of calpain-mediated proteolysis to necrotic neuronal death has gained major research focus. This relation was revealed in ischemic and excitotoxic neural injury<sup>17</sup>. Calpain-2 cleaves the substrate after finding either of Val, Leu, or Ile residues in the target protein. It cleaves in the second (P2 position) after Val, Leu, or Ile amino acid is found in the first (P1 position). Accordingly, the P2 position in the target protein can be any residue (for example, Tyr, Gly, Arg) (as shown in Table 1)<sup>18</sup>.

**>BetaII-spectrin from GeneBank M96803**

MTTTVATDYDNIIEIQQYSDVNNRW**DVDLW**DNENSSARLFERSRIKALADEREAVQKTKFTKWNVSHLARVSCRITDLYT**DLR**  
 GRMLIKLLEVLGSRERLPKPTKGRMRIHCLENVDKALQFLKEQRVHLENMGSH**DTIV**GNHRLTLGLIWTIIIRFQIQDISVETED  
 NKEKKSADALLWCQMKTAGYPNVNIHNFTTSWRDGMFANALIKHRP**DLID**FDKLLKSNAHYNLQNAFNLAEQHLGLTKLL**D**  
**PEI**ISV**DHPD**EKSIITYVVTYYHYFSKMKALAVEGKRIGKVLNDAIETEKMIKEYESLASDLELWIEQTTIIILNRRKFNANSLV  
 VQQQLQAFNTYRTVEKPKFTTEKGNLEVLFTIQSKMRANQKVYMPREGKLI SDINKAWERLEKAEHERELALRNELIRQEKL  
 EQLARFRDRKAAMRETWLSNQRLVSDNFGFDLPAVEAATKKHEAETDIAAYEERVQAVVAVARELEAENYHDIKRITARKD  
 NVIRLWEYLELELRARRQRLEMNLGLQKIFQEMLYIM**DWMD**EMKVLVLSQDYGKHLGVEDLLQKHTLVEADIGIQAERVGVN  
 ASAQKFATDGEYKPCDPQVIRDRVAHMEFCYQELCQLAAERRARLEESRRLWKFWEAAEEEGWIREKEKILSSDDYGKDLTS  
 VMRLLSKHRAFEDEMSGRSGHFQAIKEGEDMIAEEHFGSEKIRIRIYIYREQWANLEQLSAIRKKRLEEASLLHQFQA**DADDI**  
**D**AWMLDILKIVSSSDVGHDEYSTQSLVKKHKDVAEEIANYPRLDTLHEQASALPQEAHESPDVGRRLSGIEERYKEVAELTRL  
 RKQALQDTLALYKMFSEADACELWIDEKEQWLNMQIPEKLEDEVIQHRFESLEPEMNNQASRVAVVNQIARQLMHSQHPSEK  
 EIKAQDQKLNTRWSQFRELVDKRDALLSALS IQNYHLECNETKSWIREKTKVIESTQDLGNDLAGVMALQRKLTGMRDLVAI  
 EAKLSDLQKEAEKLESEHPDQAAILSLRAEISDVWEEMKTLKNREASLGEASKLQQFLR**DLDD**FQSWLSRTQTAIASEDMPN  
 TLTEAEKLLTQHENIKNEIDNYEEDYQKMRDMGEMVTQGQTDAYMFLRQLRALDTGWNLHKMWENRQNLSSQSHAYQQFLR  
 DTQKQAEAFLNQYVLAHTEMPPTLEGAEAAIKKQEDFMTMDANEKINAVVETGRRLVSDGNINSRDIQEKV**DSID**DRHRKN  
 RETASELLMRLK**DNRD**LQKFLQDCQELSLWINEKMLTAQDMSYDEARNLHSHKWLKHQAFMAELASNKELDKIEKEGMQLISEK  
 PETEAVVKEKLTGLHKMWEVLESTTQTKAQLFDANKAELFTQSCADLDKWLHGLESQLQSDDYGKHLTSVNIILLKQOQMLENQ  
 MEVRKKEIEELQSQALSQEGKST**DEVD**SKRLTVQTKFMELLEPLNERKHNLLASKEIHQFN**DVEI**EILVWGERMPLATSTD  
 HGHNLTQVQLLIKKNQTLQKEIQGHQPRIDDI FERSQNI VTDSSLSAEAIRQLADLKQLWGLLIEETEKRHRRLLEAHRAQQ  
 YYFDAEAEAWMSEQELYMSEEKAKDEQSAVSMLKKHQILEQAVEDYAETVHQLSKTSRALVADSHPESEIRISMRQSKVDKLY  
 AGLKDLAEERRGKLDERHRLFQLNREVDDLEQWIAEREVVAGSHELQDYEHVTMLQERFREFARDTGNIGQERVDTVNHLADE  
 LINSGHSDAATIAEWKDGLENAWADLLELIDTRTQILAAASYELHKFYHDAKEIFGRIQDKHKKLPEELGRDQNTVETLQRMHTT  
 FEHDIQALGTQVRQLQEDAARLQAAYAG**DKAI**DIQKRENEVLEAWKSLLDACESRVRV**DTG**KFRFFSMVRDLMLWMEVDVIR  
 QIEAQEKPRDVSSVELLMNHNQGIKAEIDARNDSTFTTCIELGKSL LARKHYASEEIKEKLLQLTEKRKEMIDKWEDRWELRLI  
 LEVHQFSRDASVAEAWLLGQEPYLSREIGQSVDEVEKLIKREHAEFEKSAATWDERFSALERLTTLELLEVRQQEEEEKRRP  
 PSEPESTKVSEEAESQQQWDTSKGEQVSONGLPAEQGSPRAETVDTSEMVNGATEQRTSSKESP IPSPTSDRKAKTALPAQS  
 AATLPARTQETPSAQMEGFLNRKHEWEAHNKKASSRSWHNVYCVINNQEMGFYKDAKTAASGIPYHSEVPVSLKEAVSALDY  
 KKKKHVFKLRLNDGNEYLFQAKDDEEMNTWIAISSAISSDKHEVSASTQSTPASSRAQLTPTSVVTTITSESSPGKREKDKED  
 KEKRFSLFGKKK

▼ Caspase Cleavage

Caspase Cleavage ▼

**Figure 2. Cleavage sites of  $\beta$ II-spectrin by caspase-3.** The figure shows all the consensus subsequences predicted by the algorithm, surrounded in boxes, and obeying the amino acid sequence DXXD (D stands for Asp amino acid and X can be any amino acid). In particular, the red boxes represent the consensus occurrences validated experimentally. In addition, the figure shows the cleavage site where caspase-3 cleaves.

**Combined Cleavages of Calpain-2 and Caspase-3.** Calpain-2 protease is usually activated before caspase-3. This temporal profile allows both proteases to cleave one protein substrate at separate cleavage sites without interference. It is possible though, in a random and infrequent instance, for calpain-2 and caspase-3 to be activated concurrently. Some injury models reveal the synchronized activation of both proteases like the *in vivo* model of traumatic brain injury (TBI), which affects different areas of the brain. In addition, other neuronal injury mechanisms, demonstrating the activation of both proteases, include NMDA, kainate, and glucose-oxygen-deprivation cerebrocortical neurons<sup>28–30</sup>.

**Input Data.** The algorithm needs to be validated with real data to verify its accuracy and effectiveness. Thus, the substrate  $\beta$ II-spectrin is used for input data, as shown in Supplementary Fig. 1. In addition, the mouse genome is also used as input data to test the efficiency of the algorithm on a large dataset<sup>31</sup>.

**Output of  $\beta$ II-spectrin Cleavage by Caspase-3.** The pattern DXXD $\uparrow$ X corresponds to the consensus sequence for caspase-3 protease, where X represents any one amino acid from the twenty primary amino acids, symbol  $\uparrow$  represents the site of cleavage, and D represents Aspartic acid (Asp) amino acid. All different combinations of the above pattern correspond to 400 expected instances in total. The partial amino acid subsequences, presented in Fig. 2, highlight caspase-3 consensus occurrences showing two *hits* in red that are validated experimentally<sup>16,32</sup>. Figure 2 also shows caspase-3 protease cleavage mode in cleaving an input protein sequence substrate<sup>25</sup>. The results of applying CFPA-CalpCasp algorithm on  $\beta$ II-spectrin input protein sequence and caspase-3 protease are shown in Table 2. The table indicates all the consensus occurrences (*hits*) detected by caspase-3 protease for cleavage, including the cleavage site corresponding to each consensus occurrence. The start and end positions of each consensus occurrence within the given input protein sequence are also indicated. Furthermore, the table shows all the fragments generated from cleaving the input protein sequence, at the detected consensus occurrences and cleavage sites, including their start and end positions.

From the detected hits, we list the specific subsequences ‘DEVD’ and ‘DSID’, which are validated against the experimentally generated fragments<sup>16,32</sup>. Motif ‘DSID’ starts at position 1251 (or P1251) and ends at position 1254 (or P1254) within  $\beta$ II-spectrin input protein sequence. The corresponding cleaved subsequence fragments are ‘MTT...DSID’, which starts at position 1 (P1) and ends at position 1254 (P1254), and ‘DRHR...GKKK’, which starts at position 1255 (P1255) and ends at position 2364 (P2364). On the other hand, the start position of motif



		AA Sequence	Start	End			AA Sequence	Start	End
<b>1</b>	<b>Consensus</b>	DVDD	26	29	<b>10</b>	<b>Consensus</b>	DDID	754	757
	<b>Fragment</b>	MTTT.... DVDD	1	29		<b>Fragment</b>	MTTT.... DDID	1	757
	<b>Fragment</b>	WDNE.... GKKE	30	2364		<b>Fragment</b>	AWML.... GKKE	758	2364
<b>2</b>	<b>Consensus</b>	DDWD	28	31	<b>11</b>	<b>Consensus</b>	DLDD	1070	1073
	<b>Fragment</b>	MTTT.... DDWD	1	31		<b>Fragment</b>	MTTT.... DLDD	1	1073
	<b>Fragment</b>	NENS.... GKKE	32	2364		<b>Fragment</b>	FQSW.... GKKE	1074	2364
<b>3</b>	<b>Consensus</b>	DLRD	81	84	<b>12</b>	<b>Consensus</b>	DSID	1251	1254
	<b>Fragment</b>	MTTT.... DLRD	1	84		<b>Fragment</b>	MTTT.... DSID	1	1254
	<b>Fragment</b>	GRML.... GKKE	85	2364		<b>Fragment</b>	DRHR.... GKKE	1255	2364
<b>4</b>	<b>Consensus</b>	DIVD	137	140	<b>13</b>	<b>Consensus</b>	DNRD	1273	1276
	<b>Fragment</b>	MTTT.... DIVD	1	140		<b>Fragment</b>	MTTT.... DNRD	1	1276
	<b>Fragment</b>	GNHR.... GKKE	141	2364		<b>Fragment</b>	LQKF.... GKKE	1277	2364
<b>5</b>	<b>Consensus</b>	DLID	218	221	<b>14</b>	<b>Consensus</b>	DEV D	1454	1457
	<b>Fragment</b>	MTTT.... DLID	1	221		<b>Fragment</b>	MTTT...DEV D	1	1457
	<b>Fragment</b>	FDKL.... GKKE	222	2364		<b>Fragment</b>	SKRL...GKKE	1458	2364
<b>6</b>	<b>Consensus</b>	DPED	252	255	<b>15</b>	<b>Consensus</b>	DVED	1493	1496
	<b>Fragment</b>	MTTT.... DPED	1	255		<b>Fragment</b>	MTTT.... DVED	1	1496
	<b>Fragment</b>	ISVD.... GKKE	256	2364		<b>Fragment</b>	EILW.... GKKE	1497	2364
<b>7</b>	<b>Consensus</b>	DHPD	259	262	<b>16</b>	<b>Consensus</b>	DKAD	1877	1880
	<b>Fragment</b>	MTTT.... DHPD	1	262		<b>Fragment</b>	MTTT.... DKAD	1	1880
	<b>Fragment</b>	EKSL.... GKKE	263	2364		<b>Fragment</b>	DIQK.... GKKE	1881	2364
<b>8</b>	<b>Consensus</b>	DWMD	542	545	<b>17</b>	<b>Consensus</b>	DTGD	1909	1912
	<b>Fragment</b>	MTTT.... DWMD	1	545		<b>Fragment</b>	MTTT.... DTGD	1	1912
	<b>Fragment</b>	EMKV.... GKKE	546	2364		<b>Fragment</b>	KFRF.... GKKE	1913	2364
<b>9</b>	<b>Consensus</b>	DADD	752						
	<b>Fragment</b>	MTTT.... DADD	1						
	<b>Fragment</b>	IDAW.... GKKE	756						

**Table 2. CFPA-CalpCasp Generated Data on M96803 ( $\beta$ II-spectrin Protein Sequence) by Caspase-3.**

Table 2 shows the consensus occurrences detected by CFPA-CalpCasp algorithm, specific to caspase protease. Accordingly, it shows the detected pattern obeying DXXD (D is Aspartic Acid and X is any amino acid) and its start and end positions within the  $\beta$ II-spectrin protein sequence. Afterwards, the algorithm generates all the fragments resulting from caspase cleavage based on the corresponding consensus occurrence. The fragments are listed with their start and end positions within the  $\beta$ II-spectrin protein sequence. Red highlights show the consensus occurrences and the corresponding cleavages that are validated experimentally.

'DEV D' within  $\beta$ II-spectrin input protein sequence, is at P1454, and its end position is at P1457. The corresponding cleaved subsequence fragments are 'MTTT...DEV D', which starts at position 1 (P1) and ends at position 1457 (P1457), and 'SKRL...GKKE', which starts at position 1458 (P1458) and ends at position 2364 (P2364).

**Output of  $\beta$ II-spectrin Cleavage by Calpain-2.** The patterns of LX $\uparrow$ X, VX $\uparrow$ X, and IX $\uparrow$ X correspond to the consensus sequences of calpain-2 protease, where X represents any amino acid from the twenty primary amino acids, while symbol  $\uparrow$  represents the cleavage site, and (L, V, I) triplet maps to (Leu, Val, Ile) amino acid triplet; respectively. All different combinations of the above patterns correspond to 60 expected instances in total. The partial amino acid subsequences, pictured in Fig. 3, highlight calpain-2 consensus occurrences, showing one *hit* in red that is validated experimentally<sup>16,32</sup>. Figure 3 also shows calpain-2 protease cleavage mode in cleaving an input protein sequence substrate<sup>25</sup>. The results of applying the proposed algorithm on  $\beta$ II-spectrin input

**>BetaII-spectrin from GeneBank M96803**

MTT<sup>V</sup>ATDYDNIEIQQQYSD<sup>VN</sup>NRWD<sup>VD</sup>DWDNENSSARLFERSRIKALADEREA<sup>VQ</sup>KKFTKW<sup>VN</sup>SHLAR<sup>VS</sup>CRITDLYTDLRD  
 GRMLIKLLE<sup>VI</sup>SGERLPKPTKGRMRIHCLN<sup>VL</sup>KALQFLKEQR<sup>VH</sup>LENMGSHDI<sup>VD</sup>GNHRLTLGLIWTIIILRFQIDIS<sup>VE</sup>TED  
 NKEKKSADALLWCQMKTAGYPN<sup>VN</sup>IHNFTTSWRDGMFALIHKHPDLIDFDKLLKSNAHYNLQNAFNLAEQHGLTKLLD  
 PEDISS<sup>VI</sup>HPDEKSIITY<sup>VV</sup>TYHYFYSKMKALA<sup>VE</sup>GKRIGK<sup>VL</sup>DNAIETEKMIKEYESLADLLEWIEQTIIILNRRKFNANSL<sup>VG</sup>  
<sup>VQ</sup>QLQAFNTYRT<sup>VE</sup>KPKFTEKGNLE<sup>VL</sup>LFTIQSKMRANQK<sup>VY</sup>MPREGKLI<sup>SD</sup>INKAWERLEKAEHERELALNELIRQEKL  
 EQLARRFDRKAAMRETWLSNQRL<sup>VS</sup>QDNFGFDLPA<sup>VE</sup>AATKKHEA<sup>IE</sup>TDAAYEER<sup>VQ</sup>AV<sup>VA</sup>VA<sup>VA</sup>RELEAENYHDIKIRITARKD  
<sup>N</sup>IRLWEYLLELLRARRQRLEMNLGLQKIFQEMLYIMDWMDEM<sup>VI</sup>VL<sup>VL</sup>SQDYGKHL<sup>LG</sup>VE<sup>DL</sup>LQKHTL<sup>VE</sup>ADIGIQAER<sup>VR</sup>G<sup>VN</sup>  
 ASAQKFATDGEYKPCDPQ<sup>VI</sup>TRDR<sup>VA</sup>HMEFCYQELCQLAAERRARLEESRRLWKF<sup>FW</sup>EMAE<sup>EE</sup>EGWIREKEKILSSDDY<sup>GK</sup>DLTS  
<sup>VM</sup>RLLSKHRAFEDEMSGRSGHFEQAIKEGEDMIAEEHFGSEKIRERIIYIREQWANLEQLSAIRKKRLEASLLHQFQADADDI  
 DAWMLDILKI<sup>VS</sup>SSD<sup>VG</sup>HDEYSTQSL<sup>VK</sup>KHKD<sup>VA</sup>EEIANYRPTLDLTHEQASALPQEAHESPD<sup>VB</sup>GRLSGIEERYKE<sup>VA</sup>ELTRL  
 RKQALQD<sup>TL</sup>LALYKMFSEADACELWIDEKEQWLNMQIPEKLEDLE<sup>VI</sup>QHRFESLEPEMNNQASR<sup>VA</sup>V<sup>VN</sup>QIARQLMHS<sup>GHP</sup>SEK  
 EIKAQD<sup>KL</sup>NTRWSQFREL<sup>VI</sup>RKKDALLSALSIQNYHLECNETKSWIREKTK<sup>VI</sup>TESTQDLGNDLAG<sup>VM</sup>ALQRKLTG<sup>MER</sup>DL<sup>VA</sup>I  
 EAKLSD<sup>LQ</sup>KEAEKLESEHPDQAAILSR<sup>LAE</sup>ISD<sup>VW</sup>EEMK<sup>TT</sup>LKNREASLGEASKLQ<sup>QF</sup>LRDLDD<sup>FQ</sup>SWLSRTQ<sup>TA</sup>IAISEDMPN  
 TLTAEAKLLTQHENIKNEIDNYEEDYQKMRDMGEM<sup>VI</sup>Q<sup>Q</sup>DTAQYMF<sup>LR</sup>QRLQALDTG<sup>WN</sup>ELHKM<sup>WEN</sup>RQNLLSQSHAY<sup>QF</sup>FLR  
 DTQAEAF<sup>LNN</sup>Q<sup>EY</sup>VI<sup>AH</sup>TEMP<sup>TT</sup>LEGAEAAIKKQEDF<sup>MT</sup>MDANEKINA<sup>VE</sup>TGRRL<sup>VS</sup>DGNINS<sup>DR</sup>IQEK<sup>VI</sup>SIDDRHRKN  
 RETASELLMRLKDN<sup>RDL</sup>QKFLQDCQELSLWINEKMLTAQ<sup>DS</sup>MSYDEARNLH<sup>SK</sup>WLKHQAFMAELAS<sup>NKE</sup>WLDKIEK<sup>EG</sup>MLISEK  
 PETEA<sup>VM</sup>K<sup>E</sup>KLTLGLHKM<sup>WE</sup>VI<sup>EST</sup>TQTKA<sup>QRL</sup>FDANKAEL<sup>FT</sup>QSCADLDK<sup>WL</sup>HGLSESQIQ<sup>SD</sup>DDY<sup>GK</sup>HL<sup>TV</sup>NILLK<sup>Q</sup>QMLE<sup>NQ</sup>  
 ME<sup>VR</sup>KK<sup>E</sup>IEELQ<sup>SQA</sup>ALSQEGK<sup>ST</sup>DE<sup>VD</sup>SKRLT<sup>VQ</sup>TKF<sup>MEL</sup>LEPLNERK<sup>HN</sup>LLASKEI<sup>HQ</sup>FN<sup>RD</sup>VE<sup>DE</sup>IL<sup>WV</sup>GERM<sup>PL</sup>AT<sup>STD</sup>  
 HGHN<sup>LQ</sup>T<sup>VQ</sup>LLIK<sup>KN</sup>Q<sup>TL</sup>QKEIQGHQ<sup>PR</sup>IDDIFERSQ<sup>NI</sup>VI<sup>D</sup>SS<sup>SL</sup>SAEAI<sup>RQ</sup>RLADL<sup>KQ</sup>LWGLLI<sup>EET</sup>EKR<sup>HR</sup>RL<sup>EE</sup>AH<sup>RA</sup>Q<sup>Q</sup>  
 Y<sup>FD</sup>AAEAEAWMSE<sup>QEL</sup>YMMSEK<sup>AK</sup>DEQSA<sup>VS</sup>MLK<sup>KH</sup>Q<sup>ILE</sup>QA<sup>VE</sup>DY<sup>AE</sup>T<sup>VH</sup>Q<sup>LS</sup>K<sup>TS</sup>RAL<sup>VA</sup>D<sup>SH</sup>PE<sup>SER</sup>ISM<sup>RQ</sup>SK<sup>VD</sup>K<sup>LY</sup>  
 AGLKDLA<sup>EER</sup>RGK<sup>LDER</sup>HL<sup>FQ</sup>LN<sup>RE</sup>VD<sup>DLE</sup>Q<sup>WIA</sup>ERE<sup>VVA</sup>GS<sup>HEL</sup>GQDY<sup>EH</sup>VI<sup>ML</sup>Q<sup>ER</sup>F<sup>REF</sup>ARD<sup>TGN</sup>IG<sup>QER</sup>VI<sup>TV</sup>N<sup>HL</sup>AD<sup>E</sup>  
 LINS<sup>GH</sup>SDA<sup>ATIA</sup>E<sup>WKD</sup>GLNE<sup>AWAD</sup>LLELID<sup>TR</sup>TQ<sup>ILA</sup>ASYEL<sup>HKF</sup>YH<sup>DAKE</sup>IF<sup>GRI</sup>Q<sup>DK</sup>H<sup>KKL</sup>PEEL<sup>GRD</sup>Q<sup>NT</sup>VE<sup>TL</sup>Q<sup>RM</sup>HT<sup>T</sup>  
 FE<sup>HD</sup>I<sup>QAL</sup>GT<sup>Q</sup>VB<sup>QL</sup>Q<sup>EDA</sup>ARL<sup>QA</sup>AYAG<sup>DK</sup>ADDI<sup>QK</sup>RENE<sup>VI</sup>EAW<sup>KS</sup>LLD<sup>ACES</sup>SR<sup>VR</sup>L<sup>VT</sup>IG<sup>DK</sup>FR<sup>FF</sup>SM<sup>VR</sup>DL<sup>MW</sup>ME<sup>VD</sup>IR  
 QIEA<sup>EQ</sup>EK<sup>PRD</sup>VS<sup>VE</sup>LL<sup>MN</sup>HQ<sup>G</sup>IKAEID<sup>AR</sup>ND<sup>S</sup>FT<sup>TC</sup>IEL<sup>GK</sup>SL<sup>LARK</sup>HY<sup>ASEE</sup>I<sup>KE</sup>KL<sup>LQ</sup>LT<sup>EKR</sup>K<sup>EMI</sup>DK<sup>WED</sup>R<sup>WE</sup>WL<sup>R</sup>LI  
 LE<sup>VH</sup>Q<sup>FS</sup>R<sup>DA</sup>S<sup>VA</sup>EAW<sup>LL</sup>G<sup>QEP</sup>Y<sup>LS</sup>SR<sup>EIG</sup>Q<sup>SV</sup>LE<sup>VE</sup>KL<sup>IKR</sup>HEA<sup>FEK</sup>SA<sup>ATW</sup>DER<sup>FSA</sup>LER<sup>LTT</sup>LE<sup>LE</sup>VR<sup>Q</sup>Q<sup>EEEE</sup>E<sup>KRR</sup>P  
 PS<sup>PEP</sup>ST<sup>K</sup>VS<sup>EEA</sup>ES<sup>Q</sup>Q<sup>WD</sup>TS<sup>KGE</sup>Q<sup>V</sup>Q<sup>NG</sup>LP<sup>AE</sup>Q<sup>GS</sup>PR<sup>MA</sup>ET<sup>VD</sup>I<sup>SEM</sup>V<sup>N</sup>G<sup>ATE</sup>Q<sup>RT</sup>SS<sup>KESP</sup>IP<sup>SP</sup>T<sup>SDR</sup>K<sup>A</sup>K<sup>TAL</sup>PA<sup>QS</sup>  
 AAT<sup>L</sup>P<sup>ART</sup>Q<sup>ET</sup>PSA<sup>Q</sup>ME<sup>G</sup>FL<sup>NR</sup>K<sup>HEW</sup>E<sup>AHN</sup>K<sup>KASS</sup>R<sup>SW</sup>HN<sup>VY</sup>C<sup>VI</sup>N<sup>Q</sup>EM<sup>GFY</sup>K<sup>DAK</sup>TA<sup>AS</sup>GI<sup>PHY</sup>SE<sup>VE</sup>VS<sup>L</sup>KEA<sup>VE</sup>VA<sup>LDY</sup>  
 K<sup>KKK</sup>H<sup>VE</sup>K<sup>LR</sup>L<sup>ND</sup>GN<sup>EY</sup>L<sup>FQ</sup>AK<sup>DDE</sup>EM<sup>NT</sup>WI<sup>QAI</sup>SSA<sup>ISS</sup>D<sup>KHE</sup>VS<sup>AST</sup>Q<sup>ST</sup>P<sup>ASS</sup>RA<sup>Q</sup>TL<sup>PTS</sup>V<sup>VI</sup>IT<sup>SE</sup>SS<sup>PG</sup>K<sup>REK</sup>DK<sup>EK</sup>D  
 KE<sup>KR</sup>FS<sup>LF</sup>G<sup>KKK</sup>

▼ Calpain Cleavage

**Figure 3. Cleavage sites of  $\beta$ II-spectrin by calpain-2.** The figure shows all the consensus subsequences predicted by the algorithm, surrounded in boxes, and conforming with the amino acid sequence VX (V stands for Val amino acid and X can be any amino acid). In particular, the red box represents the consensus occurrence validated experimentally. In addition, the figure shows the cleavage site where calpain-2 cleaves.

protein sequence and calpain-2 protease are shown partially in Table 3 (see Supplementary Table 1). The table lists all the hits detected by calpain-2 protease for cleavage, including the cleavage site corresponding to each consensus occurrence, and the start and end position of each consensus occurrence within the input protein sequence. Furthermore, the table shows all the fragments generated from cleaving the input protein sequence, at the detected consensus occurrences and cleavage sites, including their start and end positions.

From the detected hits, we list the specific subsequence ‘ETVD’, which is validated against the experimentally generated fragments<sup>16,32</sup>. Motif ‘ETVD’ starts at position 2143 (or P2143) and ends at position 2146 (or P2146) within  $\beta$ II-spectrin input protein sequence. The corresponding generated sequence fragments are ‘MTTT... ETVD’ and ‘TSEM... GKKK’. The first fragment extends from position 1 (P1) through position 2146 (P2146), and the second one extends from position 2147 (P2147) through position 2364 (P2364). The other detected occurrences, such as ‘VH’, ‘VA’, ‘IK’, and ‘LM’ (see Fig. 3), did not appear in experimental results, and the reason could be linked to the rapid pace of the cleavage transitions. Particularly, the end-to-end cleavage sites may obscure the digestion of the detected sequence occurrences in a simultaneous manner, and thus may end up in undetectable occurrences by experimental techniques.

Simultaneous activation of both proteases (calpain-2 and caspase-3) has also been generated computationally and provides similar outcomes and insights to the separate activation of each protease. For experimental validation, two possibilities can arise in such a case: 1) one protease inhibits the cleavage of the other protease, or 2) one protease cleaves within the input sequence cleaved by the other protease.

**Output of Mouse Proteome Cleavage by Caspase-3.** In order to assess the efficiency of the algorithm on a large dataset, the proposed algorithm is applied on the whole mouse proteome. Supplementary Table 2 shows all the consensus occurrences that result from the cleavage of the mouse proteome input protein sequences by caspase-3. The consensus occurrences appear per each protein sequence, including their start and end positions. Red highlights in Supplementary Table 2 cover the same consensus occurrence that appears multiple times within the same input protein sequence, including all the different start and end positions. On the other hand, blue highlights cover the consensus occurrences that overlap within one protein sequence. All consensus occurrences reflect the DXXD consensus pattern, where D represents Aspartic Acid and X represents any amino acid.

Table 4 depicts a detailed case of an input protein sequence having multiple occurrences and consensus overlaps. Supplementary Table 3 shows the corresponding cleaved fragments with their start and end positions.

		AA Sequence	Start	End			AA Sequence	Start	End
<b>43</b>	<b>Consensus</b>	PDVR	820	821	<b>98</b>	<b>Consensus</b>	ETVD	2145	2146
	<b>Fragment</b>	MTTT.... PDVR	1	821		<b>Fragment</b>	MTTT...ETVD	1	2146
	<b>Fragment</b>	GRLS.... GKKK	822	2364		<b>Fragment</b>	TSEM... GKKK	2147	2364
<b>44</b>	<b>Consensus</b>	KEVA	834	835	<b>99</b>	<b>Consensus</b>	EMVN	2151	2152
	<b>Fragment</b>	MTTT.... KEVA	1	835		<b>Fragment</b>	MTTT.... EMVN	1	2152
	<b>Fragment</b>	ELTR.... GKKK	836	2364		<b>Fragment</b>	GATE.... GKKK	2153	2364
<b>45</b>	<b>Consensus</b>	LEVI	886	887	<b>100</b>	<b>Consensus</b>	HNVY	2225	2226
	<b>Fragment</b>	MTTT.... LEVI	1	887		<b>Fragment</b>	MTTT.... HNVY	1	2226
	<b>Fragment</b>	QHRF.... GKKK	888	2364		<b>Fragment</b>	CVIN.... GKKK	2227	2364

**Table 3. Few Records of CFPA-CalpCasp Generated Data on M96803 ( $\beta$ II-spectrin Protein Sequence) by Calpain-2 (see Supplementary Table 1 for all Output Records).** Table 3 shows the consensus occurrences detected by CFPA-CalpCasp algorithm, specific to calpain protease. Accordingly, it shows *few* detected patterns obeying VX (V is Valine and X is any amino acid) and its start and end positions within the  $\beta$ II-spectrin protein sequence. Afterwards, the algorithm generates all fragments resulting from calpain cleavage based on the corresponding consensus occurrence. The fragments are listed with their start and end positions within the  $\beta$ II-spectrin protein sequence. Red highlights show the consensus occurrence and the corresponding cleavage that are validated experimentally.

Nevertheless, Supplementary Table 3 lists all possible cleavage combinations of the case; Supplementary Table 3 is simplified by showing the beginning and ending of each fragment subsequence.

## Discussion

Computational prediction of biomarkers is becoming a priority for biologists, as it conserves both time and cost that would have been otherwise spent on experiments, in order to probe for biomarkers. The developed algorithm for cleaved fragments prediction (CFPA-CalpCasp) is based on Smith-Waterman algorithm and detects local subsequence similarities in a set of protein sequences<sup>25</sup>. Accordingly, alignments with deletions and insertions are pruned. Then, for every acceptable alignment, the protein sequence is cleaved at the predefined cleavage site within the consensus occurrence, and results in cleaved fragments identified by the algorithm. The consensus occurrence variants are built within the consensus pattern for calpain and caspase, such as in subsequence DXXD, where D is fixed for Asp, but X can be any amino acid.

To assess the effectiveness of the algorithm in identifying consensus subsequences, proteolysis, and fragment breakdowns generation, it is applied to  $\beta$ II-spectrin substrates. The corresponding results are validated with experimental data from the literature, demonstrating the accuracy of the algorithm. In addition, the algorithm proved its efficiency in performance by detecting all the consensus variants, cleaving them at similar cleavage site, and generating all potential BDPs with relatively low time and space complexity.

Furthermore, for a better efficiency assessment, the algorithm is applied on a large dataset (mouse genome) comprising ~30 k protein sequences<sup>31</sup>. Once more, the algorithm proved its performance efficiency by detecting the consensus variants, cleaving them at the cleavage site, and generating the resulting breakdown products (refer to Algorithm in Supplementary Fig. 2). Moreover, the results demonstrated the functionality of all “*different and possible*” types of cleavage combinations, in addition to the functionality of “*overlapping*” consensus occurrences (refer to Supplementary Table 2).

The generated data and results of this research can help guide future experiments. To make the method accessible to the scientific community, a web-based front end tool will be developed for online access by users; the application will have a database backend which will store protein substrates, relevant consensus subsequences, and the generated breakdown products (BDPs or biomarkers). The front end web interface will comprise different types of functionality. Figure 4 below presents a preliminary mockup interface of the web tool. The major functionality is that scientists will be able to select a protease, a substrate protein, and a protease cleavage mode from drop down menus; after selection of input data from the web form, they will execute the algorithm to obtain all the fragments generated upon proteases cleavage of substrate proteins. The corresponding output of biomarkers will then be presented in a list that scientists can scroll through and download for further post-processing.

Another functionality we are building into the web tool is the ability to click on a specific biomarker and output all the corresponding properties, by linking to public databases. Such information is crucial for experimentalists as it allows them to identify whether a specific biomarker has an existing antibody, instead of designing a new one. Furthermore, the above strategies can be applied to other disciplines utilizing degradomics as means for biomarker identification.





Due to the specificity of calpain-2 and caspase-3 cleavage modes, CFPA-CalpCasp looks for an exact match of every stored consensus subsequence. The consensus variants are generated by fixing certain amino acids while varying others within each stored consensus subsequence. Accordingly, the *cleavage site* becomes right after the consensus *hit*. The algorithm embeds a modification version of Smith–Waterman algorithm; it performs local sequence alignments which allow to identify all local regions within each input protein sequence that match a particular consensus sequence<sup>33</sup>. The alignments are based on dynamic programming technique which constructs a scoring table, but then removes all consensus occurrences with INserts or DELetes (INDELs). To process N input protein sequences, the algorithm executes N times.

If multiple occurrences of any consensus subsequence are found in one protein sequence, the proteases might cleave at the cleavage site of each consensus occurrence. Consequently, all different combinations of potential cleavages are possible because each combination is actually a possible cleavage incidence by nature. Accordingly, the fragment generation module, within the developed algorithm, generates different scenarios of output fragments based on the different combinations of consensus occurrences. The following represents an illustration of the different output fragments generated by the algorithm upon detecting two consensus occurrences in one protein sequence:

- (a) The algorithm generates the output fragments after cleaving the input protein sequence at the cleavage site of the first occurrence, resulting in fragment 1 and fragment 2.
- (b) The algorithm generates the output fragments after cleaving the input protein sequence at the cleavage site of the second occurrence, resulting in fragment 3 and fragment 4.
- (c) The algorithm generates the output fragments after cleaving the input protein sequence at the cleavage sites of the first and second occurrences, resulting in fragment 1, fragment 4, and fragment 5 (which is located between the two cleavage sites).

The last case c) results in many short fragments, compared to a few long ones from the first two cases a) and b).

Due to space limitations, we are not presenting the fragments generated from all combinations. Tables 2 and 3 show exact consensus matches and the corresponding cleaved fragments by caspase-3 and calpain-2 on  $\beta$ II-spectrin substrate respectively. Table 4 and Supplementary Table 3 show caspase-3 exact consensus matches from the mouse genome and the corresponding cleaved fragments. Moreover, the data shows the case of a single consensus with multiple occurrences within a single input protein sequence, including different occurrences that overlap (refer to Supplementary Table 2).

## References

1. McQuibban, G. A. *et al.* Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. *Science (New York, N.Y.)* **289**, 1202–1206 (2000).
2. Alawieh, A. *et al.* Bioinformatics approach to understanding interacting pathways in neuropsychiatric disorders. *Methods Mol Biol* **1168**, 157–172, doi: 10.1007/978-1-4939-0847-9\_9 (2014).
3. Godovac-Zimmermann, J. The 9th Siena meeting: from genome to proteome: open innovations. *Expert Rev Proteomics* **9**, 591–594, doi: 10.1586/epr.12.56 (2012).
4. Huesgen, P. F. & Overall, C. M. N- and C-terminal degradomics: new approaches to reveal biological roles for plant proteases from substrate identification. *Physiol Plant* **145**, 5–17, doi: 10.1111/j.1399-3054.2011.01536.x (2012).
5. Doucet, A. & Overall, C. M. Protease proteomics: revealing protease *in vivo* functions using systems biology approaches. *Mol Aspects Med* **29**, 339–358, doi: 10.1016/j.mam.2008.04.003 (2008).
6. Kobeissy, F. H., Sadasivan, S., Liu, J., Gold, M. S. & Wang, K. K. Psychiatric research: psychoproteomics, degradomics and systems biology. *Expert Rev Proteomics* **5**, 293–314, doi: 10.1586/14789450.5.2.293 (2008).
7. Overall, C. M. & Dean, R. A. Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. *Cancer Metastasis Rev* **25**, 69–75, doi: 10.1007/s10555-006-7890-0 (2006).
8. Knuth, D., Morris, J. & Pratt, V. Fast Pattern Matching in Strings. *SIAM Journal on Computing* **6** (1977).
9. Lipman, D. J. & Pearson, W. R. Rapid and sensitive protein similarity searches. *Science (New York, N.Y.)* **227**, 1435–1441 (1985).
10. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. *J Mol Biol* **215**, 403–410, doi: 10.1016/S0022-2836(05)80360-2 (1990).
11. Ning, Z., Cox, A. J. & Mullikin, J. C. SSAHA: a fast search method for large DNA databases. *Genome Res* **11**, 1725–1729, doi: 10.1101/gr.194201 (2001).
12. Ma, B., Tromp, J. & Li, M. PatternHunter: faster and more sensitive homology search. *Bioinformatics* **18**, 440–445 (2002).
13. Kurtz, S. *et al.* Versatile and open software for comparing large genomes. *Genome Biol* **5**, R12, doi: 10.1186/gb-2004-5-2-r12 (2004).
14. Lecroq, T. Fast exact string matching algorithms. *Information Processing Letters* **102**, 229–235, doi: 10.1016/j.ipl.2007.01.002 (2007).
15. Needleman, S. B. & Wunsch, C. D. A general method applicable to the search for similarities in the amino acid sequence of two proteins. *J Mol Biol* **48**, 443–453, doi: 0022-2836(70)90057-4 (1970).
16. Wang, K. K. *et al.* Simultaneous degradation of alphaII- and betaII-spectrin by caspase 3 (CPP32) in apoptotic cells. *J Biol Chem* **273**, 22490–22497 (1998).
17. Yuen, P.-W. & Wang, K. W. Calpain inhibitors: Novel neuroprotectants and potential anticataract agents. *Drugs of the Future* **23**, doi: 10.1358/dof.1998.023.07.858362 (1998).
18. Wang, K. K. Calpain and caspase: can you tell the difference? by Kevin K.W. Wang, Vol. 23, pp. 20–26. *Trends Neurosci* **23**, 59, doi: S0166-2236(99)01536-2 (2000).
19. Shen, Y. *et al.* Blood peptidome-degradome profile of breast cancer. *PLoS One* **5**, e13133, doi: 10.1371/journal.pone.0013133 (2010).
20. Itoh, Y. & Nagase, H. Matrix metalloproteinases in cancer. *Essays Biochem* **38**, 21–36 (2002).
21. Fuhrman-Luck, R. A. *et al.* Proteomic and other analyses to determine the functional consequences of deregulated kallikrein-related peptidase (KLK) expression in prostate and ovarian cancer. *Proteomics Clin Appl* **8**, 403–415, doi: 10.1002/prca.201300098 (2014).
22. Lopez-Otin, C. & Overall, C. M. Protease degradomics: a new challenge for proteomics. *Nat Rev Mol Cell Biol* **3**, 509–519, doi: 10.1038/nrm858 (2002).
23. Clark, T. G. *et al.* The mammalian Toll-like 1 gene, Tll1, is necessary for normal septation and positioning of the heart. *Development* **126**, 2631–2642 (1999).
24. Glantz, S. B. *et al.* Sequential degradation of alphaII and betaII spectrin by calpain in glutamate or maitotoxin-stimulated cells. *Biochemistry* **46**, 502–513, doi: 10.1021/bi061504y (2007).

25. El-Assaad, A., Dawy, Z., Nemer, G. & Kobeissy, F. Cleaved Fragments Prediction Algorithm (CFPA) application to calpain and caspase in apoptosis and necrotic cell death. *2015 IEEE International Conference on Electro/Information Technology (EIT)*, 210–215, doi: 10.1109/EIT.2015.7293342 (2015).
26. Kobeissy, F. H. *et al.* Degradation of betaII-Spectrin Protein by Calpain-2 and Caspase-3 Under Neurotoxic and Traumatic Brain Injury Conditions. *Mol Neurobiol* **52**, 696–709, doi: 10.1007/s12035-014-8898-z (2015).
27. Nicholson, D. W. & Thornberry, N. A. Caspases: killer proteases. *Trends Biochem Sci* **22**, 299–306, doi: S0968-0004(97)01085-2 (1997).
28. Nath, R., Probert, A. Jr., McGinnis, K. M. & Wang, K. K. Evidence for activation of caspase-3-like protease in excitotoxin- and hypoxia/hypoglycemia-injured neurons. *J Neurochem* **71**, 186–195 (1998).
29. Pike, B. R. *et al.* Regional calpain and caspase-3 proteolysis of alpha-spectrin after traumatic brain injury. *Neuroreport* **9**, 2437–2442 (1998).
30. Pike, B. R. *et al.* Temporal relationships between de novo protein synthesis, calpain and caspase 3-like protease activation, and DNA fragmentation during apoptosis in septo-hippocampal cultures. *J Neurosci Res* **52**, 505–520, doi: 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.0.CO;2-G (1998).
31. Bult, C. J., Eppig, J. T., Kadin, J. A., Richardson, J. E. & Blake, J. A. The Mouse Genome Database (MGD): mouse biology and model systems. *Nucleic Acids Res* **36**, D724–728, doi: 10.1093/nar/gkm961 (2008).
32. Kobeissy, F. H. *et al.* Degradation of betaII-Spectrin Protein by Calpain-2 and Caspase-3 Under Neurotoxic and Traumatic Brain Injury Conditions. *Mol Neurobiol* **52**, 696–709, doi: 10.1007/s12035-014-8898-z (2014).
33. Smith, T. F. & Waterman, M. S. Identification of common molecular subsequences. *J Mol Biol* **147**, 195–197, doi: 0022-2836(81)90087-5 (1981).

## Acknowledgements

This work was undertaken at the American University of Beirut (AUB). The research was supported by a Biomedical Research Program Project within AUBMC [Grant title: The Identification of the “Compensatory Septal Proteome” (CSP) and TII Substrates Involved in CARDIAC SEPTATION: Potential for Cardiac Defect Biomarkers; Lead PI: Georges Nemer] and by a grant from the National Council for Scientific Research (CNRS) in Lebanon [Grant title: Computational Modeling of DNA Repair Mechanism (MMR) for Understanding Defects by MMR Leading to Congenital Heart Diseases (CHD); Lead PI: Zaher Dawy]. We thank Edwyn Assaf and Alaa Kassir for their help in English Editing.

## Author Contributions

A.E. designed, developed, and tested the algorithm on real data (Mouse Genome). A.E. prepared preliminary data, cleaned and analyzed the real data, interpreted the results, and wrote the manuscript. F.K., G.N. and Z.D. assisted in the study design and examined the preliminary data. F.K., G.N. and Z.D. helped analyze the protease and bioinformatics output data. All authors assisted in the final assessment of data and reviewed the manuscript. Z.D. conceived the study design, obtained funding for the study, and revised and edited the manuscript. All authors have read and approved the final manuscript.

## Additional Information

**Supplementary information** accompanies this paper at <http://www.nature.com/srep>

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** El-Assaad, A. *et al.* Novel Bioinformatics-Based Approach for Proteomic Biomarkers Prediction of Calpain-2 & Caspase-3 Protease Fragmentation: Application to  $\beta$ II-Spectrin Protein. *Sci. Rep.* **7**, 41039; doi: 10.1038/srep41039 (2017).

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017